Page 3, section on Berinert®
In 2009, the US FDA approved Berinert® (CSL Behring), a pasteurized plasma-derived C1-INH concentrate, available for intravenous (IV) administration in patients needing ondemand therapy. This drug was also not approved for shortterm prophylaxis in the EU in 2013. but is used off-label for this purpose.
The following reference from the Head of Medicine website (EU approval document) should also be added to this statement: https://mri.cts-mrp.eu/Human/Downloads/DE_H_0481_003_ PAR.pdf Page 5, section on Haegarda®
C1-INH (SC) Haegarda®
Haegarda® and Berinert® 2000/3000 (CSL Behring) were approved (US and EU) was approved by the FDA in 2017 as the first subcutaneous C1 inhibitor concentrate, also indicated for self-administration, at the dose of 60 IU/kg twice weekly. Nevertheless, the European Medicines Agency did not formally approve the marketing of the drug. 29 2. 
